Pierre Sayad, Ph.D., M.S.

COO and Interim CMO

Dr. Pierre Sayad is a forward-thinking and accomplished biotech executive with over 22 years of proven success building and leading world-class organizations. During his tenure in the pharmaceutical and biotech industry, Dr. Sayad has launched 8 novel drugs across 14 therapeutic areas across neuroscience (depression, schizophrenia, bipolar, ADHD) and oncology (both solid tumors and hematologic malignancies).

Trained as a molecular physiologist, he has been heavily involved in the FDA approval and commercial launches of several drugs including Eli Lilly and Company’s blockbuster neuroscience drugs Zyprexa®, Cymbalta®, and Strattera®, as well as oncology drugs at Onyx Pharmaceuticals, Karyopharm Therapeutics, and Oncopeptides with Kyprolis®, Xpovio®, and Pepaxto®, respectively.

Dr. Sayad’s deep academic network of global key opinion leaders, and knowledge of pipeline assets of biotech’s across CNS and cancer will serve to help expand Zephyr’s scientific reach and partnership potential. Dr. Sayad is an alumnus of Loma Linda University School of Medicine, and Harvard Business School.